No amount of preclinical testing and focus grouping can really gauge consumer acceptance in the market place, hence this SKII magnetic eye care foray. The release emphasised again and again the consumer acceptance of the device and how pleased everyone was, and included P&G heavyweights - why would they stick their neck out if they were planning to let the OBJ interactions wither away?
Now P&G have the science (300% increased uptake), they have the branding and real market test. Something tells me that the next SKII announcement is going to be a tidal wave of activity. Imagine the media blitz that would accompany P&G revamping their whole SKII line up, it might also afford a simultaneous opportunity to penetrate the US and European markets with the brand differentiating itself from rivals?
Obviously speculation and wishful thinking aplenty there but I can't see any other reason for such wholehearted endorsement after an apparently stalled programme?
- Forums
- ASX - By Stock
- Ann: SK-II Success and Forward Planning
No amount of preclinical testing and focus grouping can really...
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WFL (ASX) to my watchlist
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable